Apimeds Pharmaceuticals US (APUS) Operating Leases (2025)

Apimeds Pharmaceuticals US (APUS) reported Operating Leases of $129454.0 for Q4 2025.

Apimeds Pharmaceuticals US (APUS) Operating Leases (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Operating Leases for 1 years, with the latest figure at $129454.0 in Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases changed N/A year-over-year to $129454.0; the trailing twelve-month figure through Dec 2025 stood at $129454.0 (changed N/A YoY), and the FY2025 full-year result was $129454.0, changed N/A from the prior year.
  • Operating Leases for Q4 2025 stood at $129454.0.
  • The five-year high for Operating Leases was $129454.0 in Q4 2025, with the low at $129454.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 129,454.00